Logo image of SELB

SELECTA BIOSCIENCES INC (SELB) Stock Fundamental Analysis

NASDAQ:SELB - Nasdaq - US8162121045 - Common Stock - Currency: USD

0.8812  -0.08 (-8%)

After market: 0.9 +0.02 (+2.13%)

Fundamental Rating

2

SELB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. Both the profitability and financial health of SELB have multiple concerns. SELB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SELB has reported negative net income.
In the past year SELB has reported a negative cash flow from operations.
In the past 5 years SELB reported 4 times negative net income.
SELB had negative operating cash flow in 4 of the past 5 years.
SELB Yearly Net Income VS EBIT VS OCF VS FCFSELB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M -60M

1.2 Ratios

SELB has a Return On Assets of -25.12%. This is in the better half of the industry: SELB outperforms 77.33% of its industry peers.
With a decent Return On Equity value of -53.55%, SELB is doing good in the industry, outperforming 63.67% of the companies in the same industry.
Industry RankSector Rank
ROA -25.12%
ROE -53.55%
ROIC N/A
ROA(3y)-12.13%
ROA(5y)-47.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SELB Yearly ROA, ROE, ROICSELB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K

1.3 Margins

SELB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SELB Yearly Profit, Operating, Gross MarginsSELB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

SELB does not have a ROIC to compare to the WACC, probably because it is not profitable.
SELB has more shares outstanding than it did 1 year ago.
SELB has a better debt/assets ratio than last year.
SELB Yearly Shares OutstandingSELB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
SELB Yearly Total Debt VS Total AssetsSELB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

SELB has an Altman-Z score of -3.16. This is a bad value and indicates that SELB is not financially healthy and even has some risk of bankruptcy.
SELB's Altman-Z score of -3.16 is in line compared to the rest of the industry. SELB outperforms 44.33% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SELB is not too dependend on debt financing.
SELB's Debt to Equity ratio of 0.21 is on the low side compared to the rest of the industry. SELB is outperformed by 69.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC11.18%
SELB Yearly LT Debt VS Equity VS FCFSELB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

A Current Ratio of 4.18 indicates that SELB has no problem at all paying its short term obligations.
With a Current ratio value of 4.18, SELB perfoms like the industry average, outperforming 42.67% of the companies in the same industry.
SELB has a Quick Ratio of 4.18. This indicates that SELB is financially healthy and has no problem in meeting its short term obligations.
SELB has a Quick ratio (4.18) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 4.18
SELB Yearly Current Assets VS Current LiabilitesSELB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

SELB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.50%.
SELB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.85%.
Measured over the past years, SELB shows a very strong growth in Revenue. The Revenue has been growing by 250.30% on average per year.
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y250.3%
Sales Q2Q%-86.63%

3.2 Future

SELB is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.87% yearly.
The Revenue is expected to decrease by -11.85% on average over the next years. This is quite bad
EPS Next Y-228.11%
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
EPS Next 5Y-28.87%
Revenue Next Year-72.53%
Revenue Next 2Y-37.57%
Revenue Next 3Y-26.62%
Revenue Next 5Y-11.85%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SELB Yearly Revenue VS EstimatesSELB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
SELB Yearly EPS VS EstimatesSELB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SELB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SELB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SELB Price Earnings VS Forward Price EarningsSELB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SELB Per share dataSELB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

SELB's earnings are expected to decrease with -34.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%

More info and screens

0

5. Dividend

5.1 Amount

SELB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SELECTA BIOSCIENCES INC

NASDAQ:SELB (11/13/2023, 8:15:05 PM)

After market: 0.9 +0.02 (+2.13%)

0.8812

-0.08 (-8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/bmo
Earnings (Next)02-29 2024-02-29/amc
Inst Owners4.73%
Inst Owner Change0%
Ins Owners2.74%
Ins Owner Change0%
Market Cap135.20M
Analysts81.67
Price Target3.57 (305.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.65%
Min EPS beat(2)-57.51%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)-161.99%
Min EPS beat(4)-758.49%
Max EPS beat(4)153.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.2%
Min Revenue beat(2)-53.61%
Max Revenue beat(2)-50.8%
Revenue beat(4)1
Avg Revenue beat(4)-20.74%
Min Revenue beat(4)-53.61%
Max Revenue beat(4)40.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.55%
EPS NY rev (1m)0%
EPS NY rev (3m)15.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)60.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.32
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.12%
ROE -53.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.13%
ROA(5y)-47.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.09%
Cap/Sales 1.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 4.18
Altman-Z -3.16
F-Score2
WACC11.18%
ROIC/WACCN/A
Cap/Depr(3y)97.44%
Cap/Depr(5y)77.79%
Cap/Sales(3y)2.43%
Cap/Sales(5y)21.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y-228.11%
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
EPS Next 5Y-28.87%
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y250.3%
Sales Q2Q%-86.63%
Revenue Next Year-72.53%
Revenue Next 2Y-37.57%
Revenue Next 3Y-26.62%
Revenue Next 5Y-11.85%
EBIT growth 1Y-276.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.04%
OCF growth 3YN/A
OCF growth 5YN/A